ABSTRACT
Surgical treatment of clinical stage T3 carcinoma remains controversial, and for some authors it remains a contraindication, mainly due to an increased risk of positive surgical margins, lymph node metastases, and a less favorable long-term outcome. The arguments in favor of surgical treatment of clinical T3 tumors are the potential for adjuvant external beam radiotherapy where there are positive margins, and the avoidance of complications associated with locally advanced disease. According to the European Association of Urology Guidelines, surgery can be considered as a therapeutic option for patients with clinical T3 carcinoma of the prostate, but it should be remembered that endoscopic extraperitoneal radical prostatectomy (EERPE) for clinical T3 cancer requires considerable experience and should be avoided by beginners. Invasive intraoperative monitoring with a central line is not necessary and only two peripheral venous lines are placed.
